Journal article icon

Journal article

Antibody therapy for rheumatoid arthritis.

Abstract:

High-quality monoclonal antibodies (mAbs) with specificity for relevant disease molecules can now be produced in abundance. Anti-tumour necrosis factor-alpha therapies have set a new standard for symptom control in rheumatoid arthritis, and blockade of tumour necrosis factor has the potential to protect joints from structural damage. Other targets for therapeutic antibodies include the cytokines interleukin (IL)-1, IL-6, IL-8, IL-15, IL-17 and IL-18. In addition, there is preliminary evidence...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Role:
Author
Journal:
Current opinion in pharmacology
Volume:
3
Issue:
3
Pages:
323-328
Publication date:
2003-06-05
DOI:
EISSN:
1471-4973
ISSN:
1471-4892
URN:
uuid:5285acb2-db50-4730-924c-56ebbc331d7d
Source identifiers:
227095
Local pid:
pubs:227095

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP